KYSE-30

KYSE-30

Cat.No.: CSC-C0405

Species: Homo sapiens (Human)

Source: Esophagus

Morphology: adherent, epitheloid with long processes growing in monolayers

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0405
Description
Derived from well differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 64-year-old Japanese man prior to treatment; cell line established from tumor cells heterotransplanted into athymic mice; described to be heterotransplantable in athymic mice and to carry p53 mutation and amplification of cERB B, MYC and CYCLIN D1
Species
Homo sapiens (Human)
Source
Esophagus
Recommended Medium
Culture Properties
monolayer
Morphology
adherent, epitheloid with long processes growing in monolayers
Karyotype
Highly rearranged hypertriploid karyotype with 8% polyploidy - 66-74<3n>Xder(X), -Y, +1, +1, -5, +7, -9, -10, -15, +16, -18, -18, -19, -21, -21, -21, -22, -22, +12-15mar, t(X;2)(p11;p11), ins(1;1)(p34/36;q21q32), add(1)(q11), der(1)add(1) (p21)(q22), del(
Disease
Esophageal Squamous Cell Carcinoma
Quality Control
Mycoplasma: contamination was eliminated with BM-Cyclin (tiamulin & minocycline), then negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cy
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 3 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
Kyse-30; KYSE 30; KYSE30; Kyse30; KYSE0030
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Derived from a well-differentiated invasive esophageal squamous cell carcinoma resected from a 64-year-old Asian male prior to treatment, KYSE-30 is a prototypic human ESCC line established via initial heterotransplantation in athymic mice. Its extensively characterized genomic landscape and stable phenotype position it as a cornerstone model for dissecting ESCC pathogenesis and therapeutic response.

KYSE-30 harbors a pathogenic TP53 splice-site mutation (intron 6) alongside CDKN2A and HRAS mutations, coupled with high-level co-amplification of MYC, ERBB2 (c-ERB B), and CCND1. This combinatorial genotype faithfully recapitulates the core oncogenic circuitry prevalent in human ESCC.

Genomic profiling reveals that cell cycle gene mutations occur at low frequency across ESCC lines; KYSE-30 is one of only two lines (with TE-1) exhibiting this distinct mutational class. This exclusivity renders it indispensable for studying G1/S checkpoint abrogation and CDK inhibitor sensitivity in an ESCC-relevant context.

KYSE-30 expresses an exceptionally high level of epidermal growth factor receptor, providing a calibrated system for interrogating EGFR-dependent signaling, tyrosine kinase inhibitor efficacy, and receptor-targeted therapeutic strategies.

The line is heterotransplantable in nude mice, enabling in vivo efficacy studies. Engineered derivatives, including GFP-reporter stable lines, support high-content drug screening and real-time tumor tracking in preclinical models.

RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma

Oncology Letters | DOI | Paper |

Background

This study investigated the expression, clinical significance, and function of retinoblastoma-binding protein 7 (RBBP7) in esophageal squamous cell carcinoma (ESCC). Immunohistochemistry and TCGA/GTEx analyses showed RBBP7 was overexpressed in ESCC tissues. High RBBP7 correlated with poor differentiation, lymph node involvement, advanced TNM stage, and shorter overall and disease-free survival. In vitro, RBBP7 knockdown did not affect proliferation or apoptosis but reduced migration and invasion, while overexpression enhanced these processes. The findings identify RBBP7 as a prognostic biomarker and promoter of ESCC invasion and migration.

Key Findings

RBBP7 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC) at both protein and mRNA levels compared with normal esophageal tissues. High RBBP7 expression is significantly associated with poor tumor differentiation, regional lymph node involvement, and advanced pathological TNM stage. Patients with higher RBBP7 expression have significantly shorter overall survival and disease-free survival. Functional experiments using ESCC cell lines showed that RBBP7 knockdown did not alter cell viability, colony formation, or apoptosis under normal conditions. However, RBBP7 knockdown markedly decreased ESCC cell migration and invasion, whereas RBBP7 overexpression enhanced both migration and invasion. These results indicate that RBBP7 serves as a novel prognostic biomarker for ESCC and plays a crucial role in promoting tumor cell migration and invasion, likely contributing to metastasis and poor clinical outcome.

Contribution

Creative Bioarray provided the human ESCC cell lines TE1, KYSE30, and KYSE150 used in this study. These authenticated cell lines enabled stable RBBP7 knockdown and overexpression, and were essential for the migration, invasion, proliferation, colony formation, and apoptosis assays that revealed RBBP7's functional role in ESCC.

RBBP7 has no effect on tumor growth and survival processes in ESCC.
Fig. 1. RBBP7 has no effect on tumor growth and survival processes in ESCC.

RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma

Oncology Letters | DOI | Paper |

Background

This study investigated the expression, clinical significance, and function of retinoblastoma-binding protein 7 (RBBP7) in esophageal squamous cell carcinoma (ESCC). Immunohistochemistry and TCGA/GTEx analyses showed RBBP7 was overexpressed in ESCC tissues. High RBBP7 correlated with poor differentiation, lymph node involvement, advanced TNM stage, and shorter overall and disease-free survival. In vitro, RBBP7 knockdown did not affect proliferation or apoptosis but reduced migration and invasion, while overexpression enhanced these processes. The findings identify RBBP7 as a prognostic biomarker and promoter of ESCC invasion and migration.

Key Findings

RBBP7 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC) at both protein and mRNA levels compared with normal esophageal tissues. High RBBP7 expression is significantly associated with poor tumor differentiation, regional lymph node involvement, and advanced pathological TNM stage. Patients with higher RBBP7 expression have significantly shorter overall survival and disease-free survival. Functional experiments using ESCC cell lines showed that RBBP7 knockdown did not alter cell viability, colony formation, or apoptosis under normal conditions. However, RBBP7 knockdown markedly decreased ESCC cell migration and invasion, whereas RBBP7 overexpression enhanced both migration and invasion. These results indicate that RBBP7 serves as a novel prognostic biomarker for ESCC and plays a crucial role in promoting tumor cell migration and invasion, likely contributing to metastasis and poor clinical outcome.

Contribution

Creative Bioarray provided the human ESCC cell lines TE1, KYSE30, and KYSE150 used in this study. These authenticated cell lines enabled stable RBBP7 knockdown and overexpression, and were essential for the migration, invasion, proliferation, colony formation, and apoptosis assays that revealed RBBP7's functional role in ESCC.

RBBP7 has no effect on tumor growth and survival processes in ESCC.
Fig. 2. RBBP7 has no effect on tumor growth and survival processes in ESCC.

CAP1 Signaling Regulates Tumor Immunity, Proliferation, and Migration in Esophageal Cancer

Esophageal cancer (ESCA) is a common malignancy with high morbidity and mortality. Our study aimed to explore the regulatory pathways of CAP1 in ESCA and its effects on tumor immunity.

Bioinformatics analysis using LASSO Cox regression demonstrated that CAP1 carried the highest risk coefficient (0.4437) in the prognostic model. The risk score model demonstrated excellent predictive performance in the TCGA cohort and was successfully validated in external GEO datasets. High expression of CAP1 in ESCA cells enhanced their proliferative, migratory, and invasive capabilities. In a co-culture system, silencing CAP1 in ESCA cells enhanced the cytotoxicity of CD8+ T cells and reduced their apoptosis. The transcription factor ELF1 promoted CAP1 expression by binding to its promoter, thereby regulating immune evasion and tumor progression in ESCA. Importantly, in vivo experiments confirmed that knockdown of either ELF1 or CAP1 significantly suppressed tumor growth, enhanced CD8+ T cell infiltration, and downregulated PD-L1 expression, demonstrating that ELF1 promotes tumor progression and immune escape in ESCA via CAP1.

(A, B) CAP1 expression in esophageal epithelial cells and ESCA cell lines. (C) CAP1 expression at three knockdown sites in KYSE-30 cells. (D, E) qRT-PCR and Western blot detection of CAP1 expression. (F) ESCA cell viability. (G) ESCA cell proliferation.

Fig. 3. CAP1 promotes esophageal cancer (ESCA) cell proliferation (Li, Xu, et al., 2026).

(H) ESCA cell migration. (I) ESCA cell invasion.

Fig. 4. CAP1 promotes esophageal cancer (ESCA) cell migration and invasion (Li, Xu, et al., 2026).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products